[PDF] Top 20 B cell activating factor targeted therapy and lupus
Has 10000 "B cell activating factor targeted therapy and lupus" found on our website. Below are the top 20 most common "B cell activating factor targeted therapy and lupus".
B cell activating factor targeted therapy and lupus
... memory B cells from secondary lymphoid organs or to expansion of the memory pool, or even the B1 cell pool, as a homeostatic response to B-cell depletion – although it is important to note ... See full document
8
Impact of epidermal growth factor receptor (EGFR) activating mutations and their targeted treatment in the prognosis of stage IV non small cell lung cancer (NSCLC) patients harboring liver metastasis
... prognosis factor detect‑ ing an OS of 10 months when LM are present (n = 40) compared to 21 months when no liver metastases are diagnosed at the moment of stage IV NSCLC diagnosis (n = ...196). b A better ... See full document
7
PD L1(hi) B cells are critical regulators of humoral immunity
... to B-cell depletion therapy (aCD20 monoclonal antibody (mAb) ...post B-cell depletion therapy, was attributed to elevated expression of the B-cell activating ... See full document
16
B-cell-targeted therapies in systemic lupus erythematosus and ANCA-associated vasculitis: Current progress.
... In both SLE and AAV, the first priority has been to meet the unmet need for treatments that prevent life and organ threatening inflammatory disease, especially in patients resistant to conventional therapies. As this ... See full document
43
Alpha 1 antitrypsin protein and gene therapies decrease autoimmunity and delay arthritis development in mouse model
... and B-cell activity. Since CIA is a T-cell-mediated auto- immune disease, the effect of hAAT on T-cell function was examined in a T-cell proliferation ...hAAT therapy on ... See full document
13
Original Article Curcumin attenuates lupus nephritis in MRL/lpr mice by suppressing macrophage-secreted B cell activating factor (BAFF)
... ameliorated lupus progression in MRL/lpr mice, which was accompanied by a decrease of BAFF produc- tion in serum, spleen, and kidney as well as decrease of activation of B ... See full document
9
Tumor necrosis factor superfamily member APRIL contributes to fibrotic scar formation after spinal cord injury
... and B cell survival and proliferation ...systemic lupus erythemato- sus [5], multiple sclerosis [6], and schizophrenia ...9], B cells, and activated T cells [10] ex- press APRIL, and APRIL can ... See full document
8
Prognostic biomarkers for patients with advanced renal cell carcinoma treated with VEGF-targeted tyrosine kinase inhibitors
... A biomarker is a measurable characteristic which can be an indicator of a biologic process, both normal and pathologic. In oncology, biomarkers are most frequently used to indicate clinical events, such as disease onset, ... See full document
6
Rationale of anti CD19 immunotherapy: an option to target autoreactive plasma cells in autoimmunity
... Anti-CD20 therapy using rituximab directly targeting B cells has been approved for treatment of non-Hodgkin lymphoma, rheumatoid arthritis and anti-neutrophil cytoplasmic antibody-associated vasculitides ... See full document
16
Review Article Role of hypoxia-inducible factor in clear cell renal cell carcinoma and its application in targeted therapy
... only the fast-differentiating tumor cells are killed but CSCs are not and they show strong resistance to radio- and/or chemotherapy. Therefore, traditional treatment methods such as those involving the use of interferon ... See full document
9
Fichtner, Miriam Franziska Laura (2018): Features of the two isoforms of TACI/TNFRSF13B in soluble and membrane-bound form. Dissertation, LMU München: Medizinische Fakultät
... of B-cells is regulated by the two cytokines B-cell activating factor (BAFF) and a proliferation-inducing ligand (APRIL), which bind to the receptors transmembrane activator and CAML ... See full document
126
Lupus nephritis: current update
... induction therapy appears to be ...Newer targeted therapeutics built upon recent molecular insights are likely to revolutionize how LN is managed in the clinic in the coming ... See full document
12
Peripheral regulatory cells immunophenotyping in Primary Sjögren's Syndrome: a cross sectional study
... BAFF: B cell activating factor; BCR: B cell receptor; CpG: cytosine-phopsphate-guanosine; DC: dendritic cell; DCregs: indoleamine 2,3-dioxygenase-expressing dendritic ... See full document
18
Spotlight on blisibimod and its potential in the treatment of systemic lupus erythematosus: evidence to date
... Abstract: B cells in general and BAFF (B cell activating factor of the tumor necrosis factor [TNF] family) in particular have been primary targets of recent clinical trials in ... See full document
11
B-cell targeted therapy in systemic lupus erythematosus: potential of rituximab
... patients who achieved low disease activity (BILAG C or D) at any point prior to week 52. The following variables were assessed: time to first severe flare ($1 A BILAG score or $3 B BILAG scores), time to first A ... See full document
8
BAFF- and APRIL-targeted therapy in systemic autoimmune diseases
... mature B cells and a 45 % attenuation of immunoglobulin compared to placebo ...active lupus nephritis who are taking steroids and MMF was termi- nated due to severe infection ... See full document
6
Serum BAFF and APRIL levels in patients with IgG4 related disease and their clinical significance
... BAFF: B cell-activating factor of the tumor necrosis factor family; BCMA: B cell maturation antigen; BLys: B-lymphocyte stimulator; CA II: carbonic anhydrase II; ... See full document
8
B cell targeted therapies
... of B cells expressing CD86 among all ...other cell surface marker expression among responders and ...individuals, lupus patients exhibited several abnormalities in peripheral B cell ... See full document
6
B cell targeted therapy for systemic lupus erythematosus: an update
... immunosuppressive therapy), In most of these non-controlled studies, concomitant use of significant clinical improvement was observed, with a reduction in immunosuppressive agents such as cyclophosphamide and ... See full document
12
The role of death-associated protein 3 in apoptosis, anoikis and human cancer
... The processes underlying apoptosis have been impli- cated in carcinogenesis and have thus been the subject of continued research in the context of cancer. The earliest and most well − documented apoptosis gene is the ... See full document
10
Related subjects